Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS

Canagliflozin is a novel, orally selective inhibitor of sodium-dependent glucose co-transporter-2 (SGLT2) for the treatment of patients with type 2 diabetes mellitus. In this study, a sensitive and efficient UPLC-MS/MS method for the quantification of canagliflozin and its metabolites in rat plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Song-tao, Niu, Hui-min, Wu, Yin, Jiang, Jia-lei, Li, Ying, Jiang, Kun-yu, Wang, Xin, Zhang, Mao-fan, Han, Ming-feng, Meng, Sheng-nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100046/
https://www.ncbi.nlm.nih.gov/pubmed/29783787
http://dx.doi.org/10.3390/molecules23051229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100046/
https://www.ncbi.nlm.nih.gov/pubmed/29783787
http://dx.doi.org/10.3390/molecules23051229

Ejemplares similares